Lakewood Capital Down 31% In Q1: Shorting The Following “Questionable Korean Biotech Companies” – ValueWalk Premium

Lakewood Capital Down 31% In Q1: Shorting The Following “Questionable Korean Biotech Companies”

Anthony Bozza's Lakewood Capital Management ended the first quarter of 2020 with a net loss of 31.1%.

According to a copy of the hedge fund's Q1 letter, which ValueWalk has been able to review, the firm ended the month of March with long equity exposure of 98% and short exposure of 39.8% for net exposure of 58.2%.
If you’re looking for value stocks, and exclusive access to value-focused hedge fund managers, check out

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
0